Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Faldaprevir on Raltegravir PK in Healthy Volunteers
NCT02182375Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2010
- Primary completion
- Mar 2010
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, open-label, single-arm trial of faldaprevir in hepatitis C virus infection, sponsored by Boehringer Ingelheim. Primary endpoints: Steady-state Maximum Measured Concentration at Day 15, Steady-state Area Under the Concentration-Time Curve at Day 15 and 1 more. Started Jan 2010; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02182375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182375.